Trade AstraZeneca PLC - GBP - AZNl CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.28 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.025255% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003337% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | GBP | ||||||||
Margin | 5% | ||||||||
Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
AstraZeneca PLC ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 110.42 |
Open* | 111.18 |
1-Year Change* | 12.16% |
Day's Range* | 109.63 - 111.48 |
52 wk Range | 94.99-123.92 |
Average Volume (10 days) | 995.21K |
Average Volume (3 months) | 36.82M |
Market Cap | 168.19B |
P/E Ratio | 34.26 |
Shares Outstanding | 1.55B |
Revenue | 35.66B |
EPS | 3.17 |
Dividend (Yield %) | 2.16741 |
Beta | 0.25 |
Next Earnings Date | Nov 9, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 27, 2023 | 110.42 | -1.16 | -1.04% | 111.58 | 112.82 | 110.42 |
Sep 26, 2023 | 111.50 | 0.12 | 0.11% | 111.38 | 112.48 | 110.66 |
Sep 25, 2023 | 111.26 | 0.12 | 0.11% | 111.14 | 112.48 | 110.20 |
Sep 22, 2023 | 110.42 | 1.89 | 1.74% | 108.53 | 111.76 | 108.21 |
Sep 21, 2023 | 108.49 | -0.42 | -0.39% | 108.91 | 110.64 | 108.49 |
Sep 20, 2023 | 108.13 | 0.86 | 0.80% | 107.27 | 109.31 | 106.49 |
Sep 19, 2023 | 105.77 | 0.22 | 0.21% | 105.55 | 106.25 | 105.03 |
Sep 18, 2023 | 106.37 | -2.92 | -2.67% | 109.29 | 110.14 | 106.37 |
Sep 15, 2023 | 108.43 | 0.20 | 0.18% | 108.23 | 109.92 | 107.99 |
Sep 14, 2023 | 107.41 | 1.94 | 1.84% | 105.47 | 108.07 | 105.39 |
Sep 13, 2023 | 105.27 | -1.12 | -1.05% | 106.39 | 106.69 | 105.27 |
Sep 12, 2023 | 106.83 | 1.60 | 1.52% | 105.23 | 107.11 | 105.07 |
Sep 11, 2023 | 103.99 | -3.96 | -3.67% | 107.95 | 108.31 | 103.53 |
Sep 8, 2023 | 107.33 | -0.80 | -0.74% | 108.13 | 108.71 | 107.33 |
Sep 7, 2023 | 108.05 | 2.20 | 2.08% | 105.85 | 108.17 | 105.57 |
Sep 6, 2023 | 105.99 | 0.30 | 0.28% | 105.69 | 106.53 | 105.25 |
Sep 5, 2023 | 106.45 | 0.44 | 0.42% | 106.01 | 107.85 | 106.01 |
Sep 4, 2023 | 106.77 | 0.08 | 0.07% | 106.69 | 107.89 | 106.23 |
Sep 1, 2023 | 106.87 | 0.92 | 0.87% | 105.95 | 107.23 | 105.71 |
Aug 31, 2023 | 106.83 | -0.06 | -0.06% | 106.89 | 107.89 | 106.51 |
AstraZeneca PLC - GBP Events
Time (UTC) | Country | Event |
---|---|---|
Friday, September 29, 2023 | ||
Time (UTC) 10:59 | Country GB
| Event AstraZeneca PLC at Citi European Healthcare Bus Trip AstraZeneca PLC at Citi European Healthcare Bus TripForecast -Previous - |
Monday, October 23, 2023 | ||
Time (UTC) 17:00 | Country GB
| Event AstraZeneca PLC Meet the Management European Society for Medical Oncology Congress AstraZeneca PLC Meet the Management European Society for Medical Oncology CongressForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 44351 | 37417 | 26617 | 24384 | 22090 |
Revenue | 44351 | 37417 | 26617 | 24384 | 22090 |
Cost of Revenue, Total | 8649 | 9542 | 5270 | 4824 | 4246 |
Gross Profit | 35702 | 27875 | 21347 | 19560 | 17844 |
Total Operating Expense | 40594 | 36361 | 21455 | 21460 | 18703 |
Selling/General/Admin. Expenses, Total | 13512 | 11519 | 9338 | 8964 | 8479 |
Research & Development | 9612 | 8519 | 6094 | 5320 | 5266 |
Depreciation / Amortization | 4094 | 3044 | 1897 | 1812 | 1945 |
Unusual Expense (Income) | 4820 | 3846 | -763 | 863 | -953 |
Other Operating Expenses, Total | -93 | -109 | -381 | -323 | -280 |
Operating Income | 3757 | 1056 | 5162 | 2924 | 3387 |
Interest Income (Expense), Net Non-Operating | -815 | -819 | -716 | -766 | -775 |
Other, Net | -441 | -502 | -530 | -610 | -619 |
Net Income Before Taxes | 2501 | -265 | 3916 | 1548 | 1993 |
Net Income After Taxes | 3293 | 115 | 3144 | 1227 | 2050 |
Minority Interest | -5 | -3 | 52 | 108 | 105 |
Net Income Before Extra. Items | 3288 | 112 | 3196 | 1335 | 2155 |
Net Income | 3288 | 112 | 3196 | 1335 | 2155 |
Income Available to Common Excl. Extra. Items | 3288 | 112 | 3196 | 1335 | 2155 |
Income Available to Common Incl. Extra. Items | 3288 | 112 | 3196 | 1335 | 2155 |
Dilution Adjustment | 0 | 0 | |||
Diluted Net Income | 3288 | 112 | 3196 | 1335 | 2155 |
Diluted Weighted Average Shares | 1560 | 1427 | 1313 | 1301 | 1267 |
Diluted EPS Excluding Extraordinary Items | 2.10769 | 0.07849 | 2.43412 | 1.02613 | 1.70087 |
Dividends per Share - Common Stock Primary Issue | 2.89361 | 2.84245 | 2.83031 | 2.89446 | 2.74532 |
Diluted Normalized EPS | 3.8859 | 2.22705 | 1.88804 | 1.48501 | 0.85399 |
Interest Expense (Income) - Net Operating | 0 | 0 | |||
Total Extraordinary Items |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 11416 | 10879 | 11207 | 10982 | 10771 |
Revenue | 11416 | 10879 | 11207 | 10982 | 10771 |
Cost of Revenue, Total | 1974 | 2053 | 2417 | 2118 | 1904 |
Gross Profit | 9442 | 8826 | 8790 | 8864 | 8867 |
Total Operating Expense | 8960 | 8330 | 10113 | 9737 | 10232 |
Selling/General/Admin. Expenses, Total | 4102 | 3196 | 3469 | 3353 | 3633 |
Research & Development | 2570 | 2299 | 2638 | 2357 | 2431 |
Depreciation / Amortization | 952 | 954 | 1034 | 979 | 983 |
Unusual Expense (Income) | 109 | 108 | 331 | 1002 | 1298 |
Other Operating Expenses, Total | -747 | -280 | 224 | -72 | -17 |
Operating Income | 2456 | 2549 | 1094 | 1245 | 539 |
Interest Income (Expense), Net Non-Operating | -368 | -287 | -316 | -323 | -292 |
Net Income Before Taxes | 2088 | 2262 | 778 | 922 | 247 |
Net Income After Taxes | 1820 | 1804 | 902 | 1642 | 360 |
Minority Interest | -2 | -1 | -1 | -2 | 0 |
Net Income Before Extra. Items | 1818 | 1803 | 901 | 1640 | 360 |
Net Income | 1818 | 1803 | 901 | 1640 | 360 |
Income Available to Common Excl. Extra. Items | 1818 | 1803 | 901 | 1640 | 360 |
Income Available to Common Incl. Extra. Items | 1818 | 1803 | 901 | 1640 | 360 |
Dilution Adjustment | |||||
Diluted Net Income | 1818 | 1803 | 901 | 1640 | 360 |
Diluted Weighted Average Shares | 1560 | 1560 | 1560 | 1559 | 1560 |
Diluted EPS Excluding Extraordinary Items | 1.16538 | 1.15577 | 0.57756 | 1.05196 | 0.23077 |
Dividends per Share - Common Stock Primary Issue | 0.91215 | 0 | 1.9694 | 0 | 0.93017 |
Diluted Normalized EPS | 1.22629 | 1.21098 | 0.70833 | 0.99743 | 0.80833 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 22593 | 26244 | 19544 | 15563 | 15591 |
Cash and Short Term Investments | 6405 | 6398 | 7992 | 6218 | 5680 |
Cash | 1411 | 1461 | 1182 | 755 | 893 |
Cash & Equivalents | 4755 | 4868 | 6650 | 4614 | 3938 |
Short Term Investments | 239 | 69 | 160 | 849 | 849 |
Total Receivables, Net | 9923 | 8795 | 5651 | 5181 | 4345 |
Accounts Receivable - Trade, Net | 7508 | 6324 | 3956 | 3813 | 2995 |
Total Inventory | 4699 | 8983 | 4024 | 3193 | 2890 |
Prepaid Expenses | 1329 | 1512 | 1735 | 865 | 1436 |
Other Current Assets, Total | 237 | 556 | 142 | 106 | 1240 |
Total Assets | 96483 | 105363 | 66729 | 61377 | 60651 |
Property/Plant/Equipment, Total - Net | 9449 | 10171 | 8917 | 8335 | 7421 |
Property/Plant/Equipment, Total - Gross | 17192 | 18495 | 17110 | 15852 | 14639 |
Accumulated Depreciation, Total | -7743 | -8324 | -8193 | -7517 | -7218 |
Goodwill, Net | 19820 | 19997 | 11845 | 11668 | 11707 |
Intangibles, Net | 39307 | 42387 | 20947 | 20833 | 21959 |
Long Term Investments | 1142 | 1237 | 1147 | 1459 | 922 |
Note Receivable - Long Term | 592 | 504 | 325 | 348 | 515 |
Other Long Term Assets, Total | 3580 | 4823 | 4004 | 3171 | 2536 |
Total Current Liabilities | 26293 | 22594 | 20307 | 18117 | 16292 |
Accounts Payable | 2550 | 2824 | 2350 | 1774 | 1720 |
Accrued Expenses | 8303 | 8079 | 4994 | 5085 | 5148 |
Notes Payable/Short Term Debt | 261 | 294 | 370 | 154 | 160 |
Current Port. of LT Debt/Capital Leases | 5281 | 1599 | 2016 | 1856 | 1594 |
Other Current Liabilities, Total | 9898 | 9798 | 10577 | 9248 | 7670 |
Total Liabilities | 59446 | 66095 | 51107 | 48250 | 48183 |
Total Long Term Debt | 23690 | 28888 | 17994 | 16217 | 17359 |
Long Term Debt | 22965 | 28134 | 17505 | 15730 | 17359 |
Capital Lease Obligations | 725 | 754 | 489 | 487 | 0 |
Deferred Income Tax | 2944 | 6206 | 2918 | 2490 | 3286 |
Minority Interest | 21 | 19 | 16 | 1469 | 1576 |
Other Liabilities, Total | 6498 | 8388 | 9872 | 9957 | 9670 |
Total Equity | 37037 | 39268 | 15622 | 13127 | 12468 |
Common Stock | 387 | 387 | 328 | 328 | 317 |
Additional Paid-In Capital | 35155 | 35126 | 7971 | 7941 | 4427 |
Retained Earnings (Accumulated Deficit) | 1495 | 3755 | 7323 | 4858 | 7724 |
Total Liabilities & Shareholders’ Equity | 96483 | 105363 | 66729 | 61377 | 60651 |
Total Common Shares Outstanding | 1549.8 | 1549.4 | 1312.67 | 1312.14 | 1267.04 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 22266 | 22593 | 20224 | 20917 | 22647 |
Cash and Short Term Investments | 6462 | 6405 | 4898 | 4887 | 5823 |
Cash & Equivalents | 6232 | 6166 | 4458 | 4817 | 5762 |
Short Term Investments | 230 | 239 | 440 | 70 | 61 |
Total Receivables, Net | 10797 | 11252 | 10061 | 9612 | 9050 |
Accounts Receivable - Trade, Net | 10289 | 10521 | 9336 | 8908 | 8683 |
Total Inventory | 4967 | 4699 | 5078 | 6220 | 7624 |
Other Current Assets, Total | 40 | 237 | 187 | 198 | 150 |
Total Assets | 96687 | 96483 | 94185 | 96579 | 100273 |
Property/Plant/Equipment, Total - Net | 9599 | 9449 | 9227 | 9627 | 10015 |
Goodwill, Net | 20001 | 19820 | 19707 | 19821 | 19963 |
Intangibles, Net | 39291 | 39307 | 39585 | 39900 | 41265 |
Long Term Investments | 1234 | 1142 | 1102 | 1180 | 1237 |
Note Receivable - Long Term | 682 | 835 | 792 | 881 | 864 |
Other Long Term Assets, Total | 3614 | 3337 | 3548 | 4253 | 4282 |
Total Current Liabilities | 24860 | 26293 | 24850 | 21815 | 22740 |
Payable/Accrued | 19210 | 19040 | 17694 | 17821 | 17864 |
Notes Payable/Short Term Debt | 568 | 261 | 584 | 636 | 724 |
Current Port. of LT Debt/Capital Leases | 3289 | 5281 | 5034 | 1746 | 1570 |
Other Current Liabilities, Total | 1793 | 1711 | 1538 | 1612 | 2582 |
Total Liabilities | 60898 | 59446 | 59051 | 60647 | 63933 |
Total Long Term Debt | 27646 | 23690 | 23681 | 27146 | 28805 |
Long Term Debt | 26916 | 22965 | 23013 | 26461 | 28081 |
Capital Lease Obligations | 730 | 725 | 668 | 685 | 724 |
Deferred Income Tax | 2795 | 2944 | 3479 | 5275 | 5626 |
Minority Interest | 22 | 21 | 20 | 19 | 19 |
Other Liabilities, Total | 5575 | 6498 | 7021 | 6392 | 6743 |
Total Equity | 35789 | 37037 | 35134 | 35932 | 36340 |
Common Stock | 387 | 387 | 387 | 387 | 387 |
Additional Paid-In Capital | 35159 | 35155 | 35137 | 35134 | 35131 |
Retained Earnings (Accumulated Deficit) | 243 | 1495 | -390 | 411 | 822 |
Total Liabilities & Shareholders’ Equity | 96687 | 96483 | 94185 | 96579 | 100273 |
Total Common Shares Outstanding | 1549.85 | 1549.8 | 1549.51 | 1549.48 | 1549.45 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 2501 | -265 | 3916 | 1548 | 1993 |
Cash From Operating Activities | 9808 | 5963 | 4799 | 2969 | 2618 |
Cash From Operating Activities | 5480 | 6530 | 3149 | 3762 | 3753 |
Non-Cash Items | 542 | 141 | -332 | -103 | -1276 |
Cash Taxes Paid | 1623 | 1743 | 1562 | 1118 | 537 |
Cash Interest Paid | 849 | 721 | 733 | 774 | 676 |
Changes in Working Capital | 1285 | -443 | -1934 | -2238 | -1852 |
Cash From Investing Activities | -2960 | -11058 | -285 | -657 | 963 |
Capital Expenditures | -2571 | -2200 | -2606 | -2460 | -1371 |
Other Investing Cash Flow Items, Total | -389 | -8858 | 2321 | 1803 | 2334 |
Cash From Financing Activities | -6823 | 3649 | -2203 | -1765 | -2044 |
Financing Cash Flow Items | -1047 | -178 | -101 | 4 | -67 |
Total Cash Dividends Paid | -4364 | -3856 | -3572 | -3592 | -3484 |
Issuance (Retirement) of Stock, Net | 29 | 29 | 30 | 3525 | 34 |
Issuance (Retirement) of Debt, Net | -1441 | 7654 | 1440 | -1702 | 1473 |
Foreign Exchange Effects | -80 | -62 | 12 | 5 | -38 |
Net Change in Cash | -55 | -1508 | 2323 | 552 | 1499 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 2262 | 2501 | 1723 | 800 | 553 |
Cash From Operating Activities | 3133 | 9808 | 7410 | 4480 | 3232 |
Cash From Operating Activities | 1502 | 5480 | 4000 | 2666 | 1309 |
Non-Cash Items | -391 | 542 | 172 | 15 | -12 |
Cash Taxes Paid | 225 | 1623 | 1335 | 1006 | 228 |
Cash Interest Paid | 257 | 849 | 608 | 386 | 194 |
Changes in Working Capital | -240 | 1285 | 1515 | 999 | 1382 |
Cash From Investing Activities | -1246 | -2960 | -2711 | -968 | -168 |
Capital Expenditures | -1470 | -2571 | -2017 | -906 | -363 |
Other Investing Cash Flow Items, Total | 224 | -389 | -694 | -62 | 195 |
Cash From Financing Activities | -2031 | -6823 | -6465 | -5035 | -3740 |
Financing Cash Flow Items | -840 | -1047 | -1047 | -997 | -997 |
Total Cash Dividends Paid | -3047 | -4364 | -4364 | -2971 | -2971 |
Issuance (Retirement) of Stock, Net | 4 | 29 | 11 | 8 | 5 |
Issuance (Retirement) of Debt, Net | 1852 | -1441 | -1065 | -1075 | 223 |
Foreign Exchange Effects | -11 | -80 | -86 | -35 | -9 |
Net Change in Cash | -155 | -55 | -1852 | -1558 | -685 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.5097 | 100893184 | 1200 | 2023-01-31 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 4.1998 | 65092368 | 768 | 2023-01-31 | LOW |
Investor AB | Private Equity | 3.3299 | 51608948 | 608 | 2023-01-31 | LOW |
Capital Research Global Investors | Investment Advisor | 2.9885 | 46318144 | 1187159 | 2023-03-01 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.8215 | 43729918 | -216226 | 2023-03-01 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.2154 | 34336191 | -195287 | 2023-08-01 | LOW |
Capital World Investors | Investment Advisor | 1.8533 | 28724760 | 1470886 | 2023-03-01 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 1.3109 | 20317095 | 0 | 2023-08-01 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 1.1923 | 18479536 | 71333 | 2023-08-01 | LOW |
GQG Partners, LLC | Investment Advisor | 1.0668 | 16534104 | -45058 | 2023-03-01 | MED |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.9221 | 14291718 | -714464 | 2023-08-01 | LOW |
State Street Global Advisors (UK) Ltd. | Investment Advisor/Hedge Fund | 0.7444 | 11537597 | 8907 | 2023-08-01 | LOW |
Aviva Investors Global Services Limited | Investment Advisor/Hedge Fund | 0.5501 | 8526391 | 55270 | 2023-08-01 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5489 | 8507378 | 121134 | 2023-03-01 | LOW |
Nuveen LLC | Pension Fund | 0.5441 | 8432544 | -1110811 | 2023-02-07 | LOW |
Handelsbanken Kapitalförvaltning AB | Investment Advisor/Hedge Fund | 0.5193 | 8048865 | 62522 | 2023-07-31 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 0.5141 | 7967485 | 7544 | 2023-08-01 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.4862 | 7535152 | -16872 | 2023-08-01 | LOW |
M & G Investment Management Ltd. | Investment Advisor | 0.4825 | 7477805 | 87130 | 2023-08-01 | LOW |
Union Investment Privatfonds GmbH | Investment Advisor | 0.4153 | 6437102 | 654523 | 2023-03-31 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
AstraZeneca - GBP Company profile
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, AstraZeneca plc revenues increased 41% to $37.42B. Net income decreased 96% to $112M. Revenues reflect Farxiga segment increase of 53% to $3B, Calquenc segment increase from $522M to $1.24B, Tagrisso segment increase of 16% to $5.02B, United States segment increase of 35% to $12.05B, United Kingdom segment increase of 86% to $3.25B, Sweden segment increase from $1.03B to $2.32B.
Industry: | Pharmaceuticals (NEC) |
1 Francis Crick Avenue
CAMBRIDGE
CAMBRIDGESHIRE CB2 0AA
GB
Income Statement
- Annual
- Quarterly
News

How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com